Corline Biomedical: Short-term triggers to unlock value - Redeye

Redeye initiates coverage of Corline Biomedical, a Swedish medtech/biotech company specialising in coating solutions for the medical technology industry and transplantation clinics. With its partner Kardium expected to enter the commercial stage in 2026e, we anticipate a significant sales uptick. Our fair value range suggests a substantial upside, supported by several key catalysts linked to Kardium’s product launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/1072392/corline-biomedical-short-term-triggers-to-unlock-value?utm_source=finwire&utm_medium=RSS